Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: S095018, S095024, S095029, S095018 Recommended Dose Expansion (RDE), S095024 RDE, S095029 RDE, Cemiplimab; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Detroit, Michigan • Canton, Ohio • Columbus, Ohio

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 64 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 9 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 13
States / cities: West Palm Beach, Florida • Chicago, Illinois • Charlotte, North Carolina + 10 more

Conditions: Musculoskeletal Pain
Interventions: Emotional Awareness and Expression Therapy, Cognitive Behavior Therapy; Behavioral
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 50 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain, Gender Identity
Interventions: Quantative sensory testing, Blood Draw; Behavioral · Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: Radiation therapy; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Bronchopulmonary Dysplasia, Chronic Lung Disease
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 1 Day to 4 Months
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Allergic Conjunctivitis
Interventions: olopatadine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Standard Training, Online Training
Interventions: Training Website, Control; Other
Lead sponsor: Temple University; Other
Eligibility: Not listed
Enrollment: 512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Osteoarthritis
Interventions: Not listed
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 40 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: John F. Foley, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Primary Hyperoxaluria
Interventions: Genetic Analysis; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: Not listed
Enrollment: 902 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: MI condition, GI; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Minneapolis, Minnesota

Conditions: Migraine Disorders
Interventions: Emotional Awareness and Expression Therapy; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Respiratory Distress Syndrome, Respiratory Distress Syndrome, Adult
Interventions: Respiratory epithelial cell brushing; Diagnostic Test
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Month to 18 Years
Enrollment: 76 participants
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Maraviroc; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Torrance, California

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Melanoma
Interventions: Ensartinib, ALKATI by Customized Nanostring Assay; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Middletown, New Jersey • Montvale, New Jersey • East White Plains, New York + 1 more

Conditions: Postural Tachycardia Syndrome
Interventions: NET mRNA level, Plasma catechols, Urine Catechols; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 13 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Graft Rejection, Heart Diseases
Interventions: Endomyocardial biopsy, AlloMap Molecular Testing; Procedure
Lead sponsor: XDx; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: HIV Infections
Interventions: Placebo, Aprepitant; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Digoxin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

A Study to Examine Changes in GIP Plasma Levels Following Gastric Bypass Surgery in Obese Patients

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer

Emotional Awareness and Expression Therapy (EAET) or Cognitive Behavior Therapy (CBT) for Older Veterans With Chronic Musculoskeletal Pain

State of Hormones Impact Nociceptive Expression

Cytokine Expression During Radiation for Breast Cancer

Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes

Effect of Olopatadine on Allergic Tear Mediators

Ethical, Legal, and Social Issues Substudy in Relation to the GTEx Project

Anti-inflammatory Agents and Cholesterol Metabolism

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

Primary Hyperoxaluria Mutation Genotyping

Intervention to Improve Expression of End of Life Preferences for Homeless Persons

Emotional Awareness and Expression Therapy (EAET) for Migraine

Identifying PARDS Endotypes

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

Vitamin A, Its Receptors and Asthma

Treating Patients With Melanoma and ALK Alterations With Ensartinib

POTS NET mRNA Functional Correlation With NET Activity

A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer